Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Search
Tuesday, November 5, 2024
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Vanderlande Acquires Siemens Logistics
Siemens Boosts Industrial Software and AI Leadership with Altair Acquisition
Thomas Guldager Named VP of Operations at Lifecore Biomedical
Avation Medical Announces Jason Whiting as CEO
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Home
Tags
QOL Medical
QOL Medical
Biotechnology
QOL Medical, LLC Selects Optum Frontier Therapies as an Exclusive Pharmacy Partner to Best Support Congenital Sucrase-Isomaltase Deficiency Patients on Sucraid Oral Solution
PR Newswire
-
April 18, 2022
QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, announced it has selected Optum Frontier Therapies as its new pharmacy partner to support CSID...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
Vanderlande Acquires Siemens Logistics
Siemens Boosts Industrial Software and AI Leadership with Altair Acquisition
Thomas Guldager Named VP of Operations at Lifecore Biomedical
Load more
